Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study

Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study

Purpose We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic. Methods Women were selected from the Netherlands Cancer Registry. For...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2023-01, Vol.197 (1), p.161-175
Hauptverfasser: Eijkelboom, Anouk H., de Munck, Linda, Menke-van der Houven van Oordt, C. Willemien, Broeders, Mireille J. M., van den Bongard, Desiree H. J. G., Strobbe, Luc J. A., Mureau, Marc A. M., Lobbes, Marc B. I., Westenend, Pieter J., Koppert, Linetta B., Jager, Agnes, Siemerink, Ester J. M., Wesseling, Jelle, Verkooijen, Helena M., Vrancken Peeters, Marie-Jeanne T. F. D., Smidt, Marjolein L., Tjan-Heijnen, Vivianne C. G., Siesling, Sabine
Format: Artikel
Sprache:eng
Schlagworte:
Breast cancer
Cancer
Cancer research
Cancer therapies
Chemotherapy
Coronaviruses
COVID-19
Drug therapy
Endocrine therapy
Epidemics
Epidemiology
ErbB-2 protein
Medicine
Medicine & Public Health
Oncology
Oncology, Experimental
Pandemics
Patients
Population studies
Population-based studies
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic. Methods Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1–8), transition (weeks 9–12), lockdown (weeks 13–17), and care restart (weeks 18–26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided p -value 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-022-06732-y